Amyotrophic lateral sclerosis (ALS)—known as Lou Gehrig's Disease, based on the iconic 1930s New York Yankee baseball ...

BHVN's Troriluzole awaits pivotal FDA approval in 2025, backed by $600M funding. Explore its diverse pipeline and promising ...

Biotech Biohaven has signed a non-dilutive funding deal with Oberland Capital as it awaits an FDA ruling on its ...

Currently under review in the U.S. for a rare genetic disorder, the drug is seen by some investors as critical to Biohaven’s ...

You may already be familiar with ALS, especially if you took part in the viral ice bucket challenge to raise awareness of the condition back in 2014. Now the disease, which currently has no cure ...

Eric Dane’s relationship with Rebecca Gayheart ‘wasn’t a failure,’ she says after calling off their divorce amid his ALS diagnosis ...

and a specific ALS medicine called riluzole, which can help slow down the progress of the disease. About 1 in 10 people with MND have a family history of the condition. But if someone in your ...

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with severe socio-economic impact. A hallmark of ALS pathology is the presence of aberrant cytoplasmic inclusions composed of ...

A small clinical trial with a pharmacokinetic sub-study, led by a world-renowned pharmacologist at the University of Houston, has demonstrated the promising effectiveness of the drug Riluzole for ...

The median reported survival time since onset ranges from 24 to 48 months. Riluzole is the only currently approved mildly efficacious treatment. Riluzole received marketing authorization in 1995 in ...